Quick Answer
Elicio Therapeutics, Inc. reported Stockholders Equity of $1.64 million for fiscal year 2025.
Elicio Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $1.64M | +114.5% |
| 2024 | -$11.31M | -199.5% |
| 2023 | $11.37M | +111.1% |
| 2022 | -$102.14M | -37.0% |
| 2021 | -$74.54M | +17.6% |
| 2020 | -$90.45M | -386.7% |
| 2019 | -$18.59M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.82M | +120.1% | +108.1% |
| June 30, 2025 | $1.83M | +211.0% | -79.4% |
| March 31, 2025 | $8.90M | +82.8% | +178.7% |
| December 31, 2024 | -$11.31M | -199.5% | +40.4% |
| September 30, 2024 | -$18.99M | -242.9% | -1049.3% |
| June 30, 2024 | -$1.65M | -107.0% | -133.9% |
| March 31, 2024 | $4.87M | +104.4% | -57.2% |
| December 31, 2023 | $11.37M | +111.1% | -14.4% |
- Elicio Therapeutics, Inc. showed an increase of +114.5% in Stockholders Equity compared to the prior fiscal year.
- Over the 2019–2025 period, Elicio Therapeutics, Inc.’s stockholders equity has grown by 108.8% (from -$18.59 million to $1.64 million).
- The most recent figure is from Elicio Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: